Featured Research

from universities, journals, and other organizations

Identification of central nervous system involvement for patients with AIDS-related lymphomas

Date:
May 30, 2014
Source:
Fox Chase Cancer Center
Summary:
Patients with AIDS-related lymphomas may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now. Infection with human immunodeficiency virus, or HIV, greatly increases a person's risk of being diagnosed with many lymphomas. AIDS-related lymphomas (ARL), which include diffuse large cell lymphomas and small noncleaved cell lymphomas, are particularly aggressive forms of disease.

Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now.

Related Articles


In a new study led by Fox Chase Cancer Center Hematologist and Oncologist Stefan K. Barta, MD, MS, MRCP, researchers report that CNSi -- identified at the time of an ARL diagnosis -- does not appear to have an impact on overall survival. Dr. Barta's collaborators will present the findings at the 50th Annual Meeting of the American Society of Clinical Oncology.

In the same study, he and his team found that patients with CNSi at the time of diagnosis were nearly three times as likely, on average, to have CNS relapse (CNSr) during cancer treatment. CNSr is generally associated with particularly poor prognosis. "It occurs early and usually has a poor outcome, though there are long term survivors," said Dr. Barta. He hopes a better understanding of how CNS involvement affects prognosis could lead to improvements in diagnostic tools and treatments.

Infection with human immunodeficiency virus, or HIV, greatly increases a person's risk of being diagnosed with many lymphomas. AIDS-related lymphomas (ARL), which include diffuse large cell lymphomas and small noncleaved cell lymphomas, are particularly aggressive forms of disease. The vast majority of patients -- at least 80 percent, according to the National Cancer Institute -- have stage IV disease at the time of presentation.

The central nervous system is among the most common sites outside the lymph nodes that may be involved with ARL. In 2013, as part of a study on factors that influence outcomes for patients with ARL, Dr. Barta led the assembly of a database containing medical data from more than 1500 patients newly diagnosed with AIDS-related lymphomas who participated in clinical trials in Europe and the United States between 1990 and 2010, inclusive.

In the new study, he and his colleagues used the same database to identify 880 patients with ARL whose data included complete information on central nervous system involvement (CNSi) at diagnosis and relapse (CNSr). They analyzed data to identify associations between CNSr and a variety of patient characteristics, including age, sex, CD4 count, treatment history with cART, lymphoma subtype, rituximab use, and type of initial chemotherapy. Only CNSi conferred a higher risk of relapse. CNSi was identified in 13 percent of all 880 patients at the time of diagnosis, including 27 percent of patients with Burkitt Lymphoma or Burkitt-like lymphoma and 6 percent in patients with diffuse large B-cell lymphoma.

Dr. Barta and his colleagues found that 5.3 percent of patients experienced CNSr a median of 4.2 months after diagnosis; those patients had a median overall survival of 1.6 months. Sixty-nine percent -- 607 patients -- had been treated with combination anti-retroviral therapies, or cART. These therapies, which came into use in 1996, reversed the dismal survival rates for patients with full-blown AIDS and slowed the onset of AIDS for patients infected with HIV. However, Dr. Barta and his team found that cART did not reduce the frequency of CNSr in patients diagnosed with ARL. Neither did other treatments the patients had received, which included combination chemotherapies with or without rituximab -- a monoclonal antibody that acts against B-cells.

"Over the last few years, people have realized that intrathecal CNS prophylaxis is probably inadequate, at least for diffuse large B-cell lymphomas, and many physicians have abandoned it," said Dr. Barta. Dr. Barta, whose research focuses on ARL, said his findings suggest the approaches used to identify CNS involvement may be missing many patients who are at risk of CNS relapse, and current treatments are insufficient. "A lot of patients who relapsed probably had undetected CNS involvement at diagnosis," he said. "We want to figure out if there are better strategies to identify patients at risk."


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Identification of central nervous system involvement for patients with AIDS-related lymphomas." ScienceDaily. ScienceDaily, 30 May 2014. <www.sciencedaily.com/releases/2014/05/140530133340.htm>.
Fox Chase Cancer Center. (2014, May 30). Identification of central nervous system involvement for patients with AIDS-related lymphomas. ScienceDaily. Retrieved December 19, 2014 from www.sciencedaily.com/releases/2014/05/140530133340.htm
Fox Chase Cancer Center. "Identification of central nervous system involvement for patients with AIDS-related lymphomas." ScienceDaily. www.sciencedaily.com/releases/2014/05/140530133340.htm (accessed December 19, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins